Top

Published in:

Open Access 01-12-2012 | Letter to the Editor

Molecular chaperone therapy- the future in cancer

Authors: Abdul Moid Shehzad, Om Dawani, Shehryar Munir, Syed Anas Hussain

Published in: Infectious Agents and Cancer | Issue 1/2012

Excerpt

Molecular chaperone or heat shock proteins (HSP) are vital proteins that increase cell survival by allowing it to combat stress caused by injurious stimuli through certain cyto-protective mechanisms [1]. These cyto-protective mechanisms of molecular chaperones, especially HSP 90 [2], have a negative effect designated to favor tumor growth and metastasis among breast cancer, leukemia, pancreatic and ovarian cancer [3, 4]. …

Almeida MB, Nascimento JL, Herculano AM, Crespo-López ME: Molecular chaperones : towards new therapeutic levels. Biomed Pharmacother. 2011, 65 (4): 239-243. 10.1016/j.biopha.2011.04.025.PubMedCrossRef

Paul W: Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics. Mol Cancer Ther February. 2003, 2: 131-

Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005, 10 (2): 86-103. 10.1379/CSC-99r.1.PubMedPubMedCentralCrossRef

Soti C, Csermely P: Molecular chaperones in the etiology and therapy of cancer. Pathol Oncol Res. 1998, 4 (4): 316-21. 10.1007/BF02905225.PubMedCrossRef

Pratt WB, Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003, 228 (2): 111-133.

Calderwood SK: Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006, 31 (3): 164-72. 10.1016/j.tibs.2006.01.006.PubMedCrossRef

Pratt WB, Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003, 228 (2): 111-33.

Ekman S: Hsp90 as a therapeutic target in patients with oesophageal carcinoma. Expert Opin Ther Targets. 2010, 14 (3): 317-28. 10.1517/14728221003621278.PubMedCrossRef

Soti C: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol. 2005, 146 (6): 769-80. 10.1038/sj.bjp.0706396.PubMedPubMedCentralCrossRef

10.

Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8: 55-61.CrossRef

11.

Stuart K: Calderwood, Jianlin Gong. Molecular chaperones in mammary cancer growth and breast tumor therapy. 2012, 113 (4): 1096-1103.

12.

Neckers L: Heat shock protein 90: the cancer chaperone. J Biosci. 2007, 32 (3): 517-30. 10.1007/s12038-007-0051-y.PubMedCrossRef

13.

Soti C: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol. 2005, 146 (6): 769-80. 10.1038/sj.bjp.0706396.PubMedPubMedCentralCrossRef

14.

Neckers L, Ivy SP: Heat shock protein 90. Curr Opin Oncol. 2003, 15 (6): 419-24. 10.1097/00001622-200311000-00003.PubMedCrossRef

15.

Yun BG, Matts RL: Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation. Exp Cell Res. 2005, 307 (1): 212-23. 10.1016/j.yexcr.2005.03.003.PubMedCrossRef

16.

Vasilevskaya IA, Rakitina TV, O’Dwyer PJ: Geldanamycin and its 17-allylamino- 17-demethoxy analogue antagonize the action of cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res. 2003, 63 (12): 3241-6.PubMed

17.

Kamal A: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003, 425 (6956): 407-10. 10.1038/nature01913.PubMedCrossRef

18.

Powers MV, Workman P: Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006, 13 (1): 125-35. 10.1677/erc.1.01324.CrossRef

19.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K: Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy. Mol Cancer Ther. 2012, 11 (2): 475-484. 10.1158/1535-7163.MCT-11-0755.PubMedCrossRef

Title: Molecular chaperone therapy- the future in cancer
Authors: Abdul Moid Shehzad
Om Dawani
Shehryar Munir
Syed Anas Hussain
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Infectious Agents and Cancer / Issue 1/2012
Electronic ISSN: 1750-9378
DOI: https://doi.org/10.1186/1750-9378-7-20

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm?

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study

Cervical and Oral Screening for HR-HPV types 16 and 18 among Sudanese Women Cervical Lesions

Using antimicrobial adjuvant therapy in cancer treatment: a review

Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile

HPV Prevention series

Keynote webinar | Spotlight on antibody–drug conjugates in cancer